QGEN

QIAGEND

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$39.00

+9.3% vs current

Most likely

Base case

45%

Probability

Target price

$35.00

-1.9% vs current

B-

Bear case

30%

Probability

Target price

$29.00

-18.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Headline flow remains high because the stock is still digesting the April 27, 2026 preliminary results and FY2026 outlook cut, the May 6 full-results confirmation, and the May 7 QuantiFERON workflow announcement. The May 7 anchor price of $33.51 sits below the newly cited $38-$45 post-reset analyst targets, but the revision pattern is mostly target cuts with only selective rating support; missing broader estimate-revision evidence keeps this a cautious monitoring view rather than a strong post-earnings recovery call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-08-01catalystPost-earnings reset must stabilize after FY2026 cut [#6K-2026-04-27]Medium impact

QIAGEN's SEC-furnished preliminary Q1 2026 release confirmed net sales of $492 million, down 1% CER versus an outlook for at least 1% CER growth, adjusted diluted EPS of $0.54 in line with outlook, and a reduced FY2026 outlook of about 1-2% CER sales growth with adjusted EPS of at least $2.43 CER; the near-term catalyst is whether Q2 and later updates show this was a demand rebasing rather than a deeper slowdown in QuantiFERON and U.S. Life Sciences.

2026-12-31catalystGrowth-pillar launches need to rebuild 2026 credibility [#PR-2026-01-12]High impact

Management entered 2026 targeting commercialization, regulatory and automation milestones across Sample technologies, QIAstat-Dx, QIAcuity, QDI and QuantiFERON; after the Q1 outlook cut, successful launch execution and visible H2 recovery are the main path to restoring confidence in the 2028 pillar-growth framework.

2027-12-31catalystQuantiFERON automation and AI workflow expansion extend the TB franchise [#PR-2026-05-07]High impact

QIAGEN's May 7 company release outlined a late-2027 target for a fully automated QuantiFERON Sample-to-Insight workflow integrating Diasorin LIAISON systems with Inpeco automation and a separate AI-enabled TB progression risk tool; this supports the long-term TB franchise narrative, but it is too far out to offset the current 2026 immigration-testing demand reset by itself.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology